The administration of both anti-mouse CD4 and anti-mouse CD8 neutralizing antibodies abrogated the anti-tumor effect of the combined treatment (p = 0.034, anti-CD4 versus control; p = 0.0245, anti-CD8 versus control). The gene discussed is CD8A; the disease is neoplasm.